TOMSK, RUSSIA / RankWire.AI / – Russian scientists have tested a bioactive coating designed to improve how titanium orthopaedic implants interact with bone tissue. The material uses calcium phosphate derived from hydroxyapatite and contains nitrogen compounds associated with nitric oxide formation. Laboratory tests found significantly better survival of human mesenchymal stem cells on coated surfaces than on uncoated titanium. Researchers examined the coating’s structure, chemistry, mechanical properties and biological response. Their peer-reviewed findings appeared in Applied Surface Science in 2026.
Scientists at Tomsk Polytechnic University produced the experimental coatings through reactive magnetron sputtering of a hydroxyapatite target inside a vacuum chamber. They varied the balance of nitrogen and argon during deposition to determine how each mixture changed the resulting surface. The study tested five conditions, ranging from pure nitrogen to pure argon. Researchers then measured coating thickness, surface morphology, hardness, wettability and chemical composition. They also conducted laboratory tests to assess how living human cells responded to the modified titanium.
The experiments showed that argon content affected several physical properties of the coatings. Surfaces created in pure argon were denser and harder than those deposited in pure nitrogen. Coating thickness also increased as the proportion of argon rose. Chemical analysis identified nitrogen-carbon and nitrogen-oxygen bonds on the modified surfaces. Researchers then compared human mesenchymal stem cells grown on coated titanium with cells exposed to uncoated titanium. The biological assessment examined cell viability and markers connected with bone-cell development.
Coating tests show stronger cell survival
Cell experiments recorded significantly better survival on coated surfaces than on uncoated titanium, according to the research findings. After seven days, coatings with higher nitrogen content also reduced activity in certain genes associated with early bone-cell differentiation. The cells retained their capacity for bone formation despite that change in early gene activity. Researchers evaluated these effects under controlled laboratory conditions using human mesenchymal stem cells. The study did not test the coating in patients or evaluate the clinical performance of implanted medical devices.
Researchers from Immanuel Kant Baltic Federal University and Siberian State Medical University conducted the biomedical evaluation of the material. Specialists from Saint Petersburg State University also participated in the wider research team. The project received support through Russia’s state science program. Researchers focused on finding gas mixtures that could produce useful combinations of physical, chemical and biological coating properties. Hydroxyapatite already has applications in implant coatings because its calcium phosphate composition resembles the mineral component found in human bone.
Study remains at laboratory testing stage
The research team has outlined additional testing beyond the initial seven-day cell assessment. Researchers said they intend to examine stem cells over periods ranging from 10 to 28 days. They also plan to study how quickly the coatings dissolve and measure nitric oxide release into surrounding tissue in living organisms. Those investigations were not part of the published laboratory results. The current study centers on coated titanium substrates, material characteristics and in vitro cell responses rather than outcomes from orthopaedic patients.
The findings provide detailed laboratory data on how nitrogen and argon ratios change calcium phosphate coatings applied to titanium surfaces. Researchers documented differences in thickness, density, hardness, chemical bonding and cellular response across the tested gas mixtures. The work also established that coated samples supported higher stem-cell survival than bare titanium under the study conditions. However, the research remains preclinical, and the published experiments do not establish safety or effectiveness in human patients. Further biological testing will assess properties that the current study did not examine.